Alba by Quotient™ believes in creating value for laboratories, that’s why in addition to a portfolio of high-quality blood bank reagents, we also offer:

•    Raised $51 million of new capital and reduced debt by approximately $140 million
•    Company to refocus commercial effort on Alba and expand MosaiQ into autoimmune and allergy 
 

To read the full 10-Q, please visit: quotientbd.com/page/financials-filings 

• The World Economic Forum’s New Champions Community brings together purpose driven companies of mid-size whose leadership is mindful of their impact on society and aspiring in building a better future 

Quotient hosted a key opinion leader (KOL) webinar on the current landscape and unmet needs within blood grouping and donor disease screening,

"As we continue to expect EU regulatory approval in the first quarter of calendar year of 2022, we are very excited to continue to drive our commercial efforts globally.

Quotient Limited was accredited as a Living Wage Employer. The Living Wage commitment will see that everyone working at Quotient Limited receive a minimum hourly wage of £9.50 in the UK or £10.85 in London.

NEW YORK ─ Microarray test developer Quotient has entered the market for transfusion diagnostic testing with a multiplex, multimodal platform and is eyeing the development of the system for additional diagnostic applications.